RedHill Biopharma Ltd – (NASDAQ:RDHL) was up 4% on Monday . The company traded as high as $12.25 and last traded at $11.75, with a volume of 71,476 shares trading hands. The stock had previously closed at $11.30.

A number of equities research analysts recently weighed in on RDHL shares. Zacks Investment Research cut shares of RedHill Biopharma Ltd – from a “buy” rating to a “hold” rating in a research note on Saturday, March 26th. FBR & Co restated a “buy” rating on shares of RedHill Biopharma Ltd – in a research note on Tuesday, May 3rd. Finally, Nomura Holdings Inc. restated a “buy” rating on shares of RedHill Biopharma Ltd – in a research note on Tuesday, March 29th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $26.29.

The firm’s market cap is $149.37 million. The company has a 50 day moving average of $10.74 and a 200 day moving average of $11.07.

RedHill Biopharma Ltd – (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, April 20th. The company reported $0.04 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.52. On average, equities analysts anticipate that RedHill Biopharma Ltd – will post ($1.85) EPS for the current year.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.